Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors

Journal of Clinical Neuroscience

Volumn 34, Issue , 2016, Pages 128-132

  Paldor, Iddo ^a   Pearce, Fiona C ^b   Drummond, Katharine J ^a,c   Kaye, Andrew H ^a,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Glioblastoma; IDH 1 mutation; Ki 67 proliferation index; MGMT methylation; Tumor location

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FRONTAL LOBE; GENE MUTATION; GLIOBLASTOMA; HUMAN; IDH1 GENE; MAJOR CLINICAL STUDY; MGMT GENE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR LOCALIZATION; WILD TYPE; ADULT; AGED; BRAIN NEOPLASMS; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; METHYLATION; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; FRONTAL LOBE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KI-67 ANTIGEN; MALE; METHYLATION; MIDDLE AGED; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84994130639     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2016.05.017     Document Type: Article

References (42)

1. [1] Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005), 987–996.
2. [2] Brandner, S., von Deimling, A., Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol 41 (2015), 694–720.
3. [3] Wick, W., Weller, M., van den Bent, M., et al. MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10 (2014), 372–385.
4. [4] Jansen, M., Yip, S., Louis, D.N., Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9 (2010), 717–726.
5. [5] Stummer, W., Pichlmeier, U., Meinel, T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7 (2006), 392–401.
6. [6] Brem, H., Piantadosi, S., Burger, P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345 (1995), 1008–1012.
7. [7] Sanai, N., Berger, M.S., Glioma extent of resection and its impact on patient outcome. Neurosurgery 62 (2008), 753–764 [discussion 264–6].
8. [8] Sanai, N., Polley, M.Y., McDermott, M.W., et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115 (2011), 3–8.
9. [9] Zhao, S., Wu, J., Wang, C., et al. Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS ONE, 8, 2013, e63682.
10. [10] Lau, D., Hervey-Jumper, S.L., Chang, S., et al. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. J Neurosurg 124 (2016), 1300–1309.
11. [11] Sanai, N., Berger, M.S., Extent of resection influences outcomes for patients with gliomas. Rev Neurol (Paris) 167 (2011), 648–654.
12. [12] Roberts, D.W., Valdes, P.A., Harris, B.T., et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 114 (2011), 595–603.
13. [13] Chaichana, K.L., Jusue-Torres, I., Navarro-Ramirez, R., et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 16 (2014), 113–122.
14. [14] Lacroix, M., Abi-Said, D., Fourney, D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95 (2001), 190–198.
15. [15] Orringer, D., Lau, D., Khatri, S., et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 117 (2012), 851–859.
16. [16] Curran, W.J. Jr., Scott, C.B., Horton, J., et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12 (1992), 219–227.
17. [17] Dziurzynski, K., Blas-Boria, D., Suki, D., et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes. J Neurooncol 109 (2012), 555–563.
18. [18] Allahdini, F., Amirjamshidi, A., Reza-Zarei, M., et al. Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival?. World Neurosurg 73 (2010), 128–134 [discussion e16].
19. [19] Field, K.M., Rosenthal, M.A., Yilmaz, M., et al. Comparison between poor and long-term survivors with glioblastoma: review of an Australian dataset. Asia Pac J Clin Oncol 10 (2014), 153–161.
20. [20] Li, S.W., Qiu, X.G., Chen, B.S., et al. Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J 122 (2009), 1245–1249.
21. [21] Hegi, M.E., Diserens, A.C., Gorlia, T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005), 997–1003.
22. [22] Denicolai, E., Tabouret, E., Colin, C., et al. Molecular heterogeneity of glioblastomas; does location matter?. Oncotarget 7 (2016), 902–913.
23. [23] Wang, Y., Zhang, T., Li, S., et al. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. Eur J Neurol 22 (2015), 348–354.
24. [24] Beiko, J., Suki, D., Hess, K.R., et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16 (2014), 81–91.
25. [25] Lai, A., Kharbanda, S., Pope, W.B., et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29 (2011), 4482–4490.
26. [26] Carrillo, J.A., Lai, A., Nghiemphu, P.L., et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33 (2012), 1349–1355.
27. [27] Hodges, T.R., Choi, B.D., Bigner, D.D., et al. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. J Neurosurg 118 (2013), 1176–1180.
28. [28] Parsons, D.W., Jones, S., Zhang, X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
29. [29] Yang, P., Zhang, W., Wang, Y., et al. IDH mutation and MGMT promoter methylation in glioblastoma: Results of a prospective registry. Oncotarget 6 (2015), 40896–40906.
30. [30] Amelot, A., De Cremoux, P., Quillien, V., et al. IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS One, 10, 2015, e0130596.
31. [31] Polivka, J., Polivka, J. Jr., Rohan, V., et al. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia. BioMed Res Int, 2014, 2014, 735659.
32. [32] Eckel-Passow, J.E., Lachance, D.H., Molinaro, A.M., et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372 (2015), 2499–2508.
33. [33] Thotakura, M., Tirumalasetti, N., Krishna, R., Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Cancer Res Ther 10 (2014), 641–645.
34. [34] Shah, N., Lin, B., Sibenaller, Z., et al. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS ONE, 6, 2011, e16146.
35. [35] Capper, D., Mittelbronn, M., Meyermann, R., et al. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 115 (2008), 249–259.
36. [36] Hartmann, C., Hentschel, B., Simon, M., et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19 (2013), 5146–5157.
37. [37] Combs, S.E., Rieken, S., Wick, W., et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. Radiat Oncol, 6, 2011, 115.
38. [38] Zhang, C.B., Bao, Z.S., Wang, H.J., et al. Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. J Cancer Res Clin Oncol 140 (2014), 45–51.
39. [39] Qi, S., Yu, L., Li, H., et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7 (2014), 1895–1902.
40. [40] Sonoda, Y., Shibahara, I., Kawaguchi, T., et al. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 32 (2015), 99–104.
41. [41] Ellingson, B.M., Lai, A., Harris, R.J., et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34 (2013), 533–540.
42. [42] Wang, Y., Fan, X., Zhang, C., et al. Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. J Neurooncol 120 (2014), 331–337.